Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2022-09-05 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 the Board of Directors at its Meeting held today considered and approved; 1. ....
Regulatory Filings
2022-09-05 English
Outcome of Board Meeting
Regulatory Filings Classification · 90% confidence The document text contains only placeholders for images and no textual content or substantive information. The true document length is only 173 characters, indicating it is extremely short and contains no report or detailed information. There is no indication of any report, announcement, or filing type. Given the lack of content, the document best fits the fallback category for miscellaneous or non-classifiable filings, which is Regulatory Filings (RNS).
2022-09-05 English
Board Meeting — Other business matters
Regulatory Filings Classification · 100% confidence The document text is extremely short (414 characters) and consists solely of a digital signature block with no substantive content, financial data, or report information. There is no indication of any report, announcement, or filing type. Given the lack of content and the nature of the text, it does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2022-08-29 English
LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/09/2022 ,inter alia, to consider and approve We wish to inform you that the meeting ....
Regulatory Filings Classification · 100% confidence The document text is extremely short (414 characters) and consists solely of a digital signature block with no substantive content, financial data, or report information. It does not contain any report, announcement, or detailed information. Given the lack of content and the nature of the text, it is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit other specific categories.
2022-08-29 English
Price movement
Regulatory Filings
2022-08-26 English
We refer to your mail of even date seeking clarification on significant increase in the volume of our security across the exchange in the recent past. In the matter, we wish to clarify ....
Regulatory Filings
2022-08-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.